Evidence map›Paper›PMID 26739052›Full record

ArticleJournal of virology2016

Requirement for the E1 Helicase C-Terminal Domain in Papillomavirus DNA Replication In Vivo.

Monika Bergvall, David Gagnon, Steve Titolo, Michaël Lehoux, Claudia M D'Abramo, Thomas Melendy, Jacques Archambault

Abstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Monika BergvallInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
David GagnonInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Quebec, Canada.
Steve TitoloInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada.
Michaël LehouxInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Quebec, Canada.
Claudia M D'AbramoInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Quebec, Canada.
Thomas MelendyDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA tmelendy@buffalo.edu jacques.archambault@ircm.qc.ca.
Jacques ArchambaultInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Quebec, Canada Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada tmelendy@buffalo.edu jacques.archambault@ircm.qc.ca.

Funding

Evaluation and development of E1-TopoI as a target for anti-HPV therapeuticsR01AI095632 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MELENDY, THOMAS · 2012 to 2015
$1.6M
CIHR 126103-1CIHR MOP-126103NIAID NIH HHS R01 AI095632
6 · The paper itself

Abstract

unlabelledThe papillomavirus (PV) E1 helicase contains a conserved C-terminal domain (CTD), located next to its ATP-binding site, whose function in vivo is still poorly understood. The CTD is comprised of an alpha helix followed by an acidic region (AR) and a C-terminal extension termed the C-tail. Recent biochemical studies on bovine papillomavirus 1 (BPV1) E1 showed that the AR and C-tail regulate the oligomerization of the protein into a double hexamer at the origin. In this study, we assessed the importance of the CTD of human papillomavirus 11 (HPV11) E1 in vivo, using a cell-based DNA replication assay. Our results indicate that combined deletion of the AR and C-tail drastically reduces DNA replication, by 85%, and that further truncation into the alpha-helical region compromises the structural integrity of the E1 helicase domain and its interaction with E2. Surprisingly, removal of the C-tail alone or mutation of highly conserved residues within the domain still allows significant levels of DNA replication (55%). This is in contrast to the absolute requirement for the C-tail reported for BPV1 E1 in vitro and confirmed here in vivo. Characterization of chimeric proteins in which the AR and C-tail from HPV11 E1 were replaced by those of BPV1 indicated that while the function of the AR is transferable, that of the C-tail is not. Collectively, these findings define the contribution of the three CTD subdomains to the DNA replication activity of E1 in vivo and suggest that the function of the C-tail has evolved in a PV type-specific manner. IMPORTANCE: While much is known about hexameric DNA helicases from superfamily 3, the papillomavirus E1 helicase contains a unique C-terminal domain (CTD) adjacent to its ATP-binding site. We show here that this CTD is important for the DNA replication activity of HPV11 E1 in vivo and that it can be divided into three functional subdomains that roughly correspond to the three conserved regions of the CTD: an alpha helix, needed for the structural integrity of the helicase domain, followed by an acidic region (AR) and a C-terminal tail (C-tail) that have been shown to regulate the oligomerization of BPV1 E1 in vitro. Characterization of E1 chimeras revealed that, while the function of the AR could be transferred from BPV1 E1 to HPV11 E1, that of the C-tail could not. These results suggest that the E1 CTD performs multiple functions in DNA replication, some of them in a virus type-specific manner.

Indexed as

DNA ReplicationAmino Acid SubstitutionCell Line, TumorDNA-Binding ProteinsHuman papillomavirus 11HumansProtein Structure, TertiarySequence DeletionViral ProteinsDNA-Binding ProteinsE1 protein, Human papillomavirus type 11Viral Proteins

Identifiers

PMID26739052
PMCPMC4810619

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.